1
The Oncologist & How to Prepare Papers
for Top-Tier International Journals
《肿瘤学家》期刊介绍
如何向国际一流学术期刊投稿
Authors’ Toolkit: A Practical Guide（投稿者工具包：实用指南）
© AlphaMed Press 2014
Objectives（目的）
By the end of this session, you will be able to:
在此次讲座结束时，参加讲座者应掌握以下几点：
• Describe journals’ editorial policies
描述期刊的编辑方针
• Identify the most suitable audiences for your work
确定你的稿件最适合的读者群
• Select the right journal for your manuscript
为你的稿件选择正确的投稿期刊
• Demonstrate the best practices for preparing manuscripts and
supplemental materials
使用最优方法来准备稿件和附加材料
• Develop skills for dialogue with editors
掌握一些与编辑对话的技巧
• Explain the review, revision, and resubmission procedures
解释审稿、修稿、再次投稿的过程
© AlphaMed Press 2014
2
3
Journal Selection（选择投稿期刊）
•
•
•
•
•
Whom do I want to reach (target audience)?
我想让谁阅读我的文章？ 目标读者
How do I intend to reach the desired audience?
怎样使我的文章被目标读者读到？
o Is the journal open-access? 这部期刊是开放性的吗？
How will readers access my article?
读者会怎样读到我的文章？
What type of journal will best meet my needs (general or
specific, local or international)?
哪种期刊最满足我的需求（综合性期刊还是专刊，国内还是国际
期刊）？
How soon do I need to publish the data?
我需要多快发表我的数据？
o Speed of review 审稿的速度
o Speed of publication 发表的速度
© AlphaMed Press 2014
4
Journal Selection（选择投稿期刊）
Research journal options 查找合适的期刊
• Request input from peers, mentors, librarians.
向同行、导师、图书馆相关人员寻求意见
• Research PubMed (MEDLINE) for similar topics.
从PubMed(MEDLINE)上查找相似议题
• Explore journal directories (e.g., Directory of Open Access
Journals). 查找期刊目录（例如：开放性期刊目录）
Identify your journal of choice 确定你所选择的期刊
• Determine the fit between your study and a target journal
确定你选择的期刊与你的研究的适合程度
• Research the journal thoroughly
对期刊进行全面的调查
• Consider the needs of co-authors and research sponsors
还需考虑其他作者和研究赞助者的需求
© AlphaMed Press 2014
Journal Selection（选择投稿期刊）
Considerations: 考虑因素
●
scope and aims of the journal 期刊的宗旨和涉及范围
- (e.g. narrow, broad, how well it matches your topic) (例如：范围、宽度、与你研究的
相关度)
●
typical readership (e.g., researchers, clinicians…)
典型读者类型（例如：科研人员、临床医生….)
●
●
methodology preferences, balance of reviews and original
research 期刊刊登文章的研究类型，综述和原创研究的比例
credibility and prestige of the journal, impact factor
期刊的可靠度和信誉，影响因子
●
visibility, journal accessibility 期刊的可及度
- Open access? Available on mobile? Indexed by PubMed
开放性期刊？在手机上是否可以阅览？ 是否由PubMed引录？
© AlphaMed Press 2014
5
6
Journal Selection（选择投稿期刊）
•
Review Author Instructions.
阅读投稿须知
•
Ensure article falls within the mission of the Journal.
确定投稿文章内容在期刊发表范围之内
•
Read the content of a few issues.
阅读期刊近几期的内容
© AlphaMed Press 2014
7
Pre-submission Inquiries （投稿前询问信）
•
Directed to the Editors to gauge their level of interest in
the topic of a manuscript
与编辑通信来判断他们对你的文章议题的感兴趣程度
•
Helps to determine whether the paper will likely be
considered for peer review
帮助确定文章是否会被审稿
© AlphaMed Press 2014
8
Pre-submission Inquiries（投稿前询问信）
This under-utilized tool streamlines the manuscript submission and
review process 这个不常用的方法常常会简化投稿与审稿的过程
•
Facilitates the receipt of timely and useful feedback
帮助获取来自编辑及时、有用的反馈
•
Helps clarify Instructions for Authors
帮助弄清投稿须知
•
Reduces strain on journal resources (e.g., peer reviewers)
减轻期刊相关人员的负担（例如：审稿者）
Enhances efficiency and speed of publication
提高文章发表的速度与效率
•
•
Improves transparency in article selection process
改善文章选择的透明度
© AlphaMed Press 2014
Pre-submission Inquiries（投稿前询问信）
Best Practices（最优方法）
Submit a pre-submission inquiry especially:
在下述的情况下尤其需写投稿前询问信
If you are unsure about your article’s suitability for a journal
如果你不确定你的文章是否适合在该期刊上发表
• If you have questions about the submission or review process
如果你不清楚投稿与审稿的程序
•
Provide sufficient study information for decision-making
为期刊最终决策提供充足的信息
•
•
•
•
•
Abstract 摘要
Perceived value to a journal’s audience 对该期刊读者的价值
Relationship to an existing body of work for a specific topic
与相关研究领域内一项议题的联系
Disclosure of prior submissions 公开先前投稿情况
Description of unusual circumstances 说明特殊情况
Be concise 简明
Stay open-minded if your article is not accepted 保持开明的态度
Request suggestions about more suitable journals (if not accepted)
询问编辑其他适合投稿的期刊（如果没有被该期刊接受）
© AlphaMed Press 2014
9
Pre-Submission Inquiry--Example
Dear Editors:
I plan to submit an unsolicited review manuscript entitled “Metformin is associated
with DESCRIBE
survival benefit in THE
cancer patients
with concurrent type 2 diabetes: a systemic
QUESTION（叙述研究问题）
SUMMARIZE
THE
FINDINGS（总结结果）
review
and meta-analyses”,
to Journal
of The Oncologist.
HIGHLIGHT
WHAT
IS
UNIQUE
（突出文章的独特之处）
Patients
with
type
2
diabetes
have
increased
cancer
risk
Patients
with
type
2
diabetes
have
increased
cancer
risk
and
cancer-related
Through
a
meta-analysis（荟萃分析）,
consisting
of
14topic.
This
is
the
first
review
article
and
meta-analysis
on
this
mortality,
which
can be reducedmortality,
by metformin
treatment.
However,
it is unclear
if
and
cancer-related
which
can
be
reduced
by
publications
with
9,028
found
that
there
was a
metformin
can also modulate
clinicalsubjects,
outcomes inwe
cancer
patients
with
concurrent
Publication
of
this
article
may
have
potential
to
impact
metformin（二甲双胍）
treatment.
However,
is unclear
typerelative
2 diabetes.
Since 2009,
a growing
number
of studies
compared it
metformin
survival
benefit
associated
with
metformin
treatment
options
in such
patients.
versus
non-metformin
treatment
on
survival
outcomes
of diabetic
patientsinincancer
if
metformin
can
also
modulate
clinical
outcomes
treatment,
comparedincluding
with treatment
with
otherlung,
glucosevarious
types of malignancies,
breast, colorectal,
prostate,
hepatic,
patients
with
concurrent
type
2
diabetes.
Since
2009,
andlowering
ovarian cancer,
etc.
medications
(HR = 0.60, 95% CI: 0.49–0.74). aThese
Through
a meta-analysis,
consisting
of 14compared
publications with
9,028 subjects,
we
growing
number
of
studies
metformin
versus
associations
also
observed
in subgroups
by country
found
that there was were
a relative
survival
benefit associated
with metformin
treatment,
non-metformin
treatment
onHR
survival
outcomes
of0.60,
diabetic
compared
with
with
other glucose-lowering
medications
(HR 0.40–0.60,
=
95%
(Asian
ortreatment
Western
countries:
= 0.49,
95% CI:
CI: 0.49–0.74).
These
associations
were
also
observed in subgroups
by country
patients
in
various
types
of
malignancies,
including
breast,
Asian
countries;
HR
=
0.67,
95%
CI:
0.52–0.85,
Western
(Asian or Western countries: HR = 0.49, 95% CI: 0.40–0.60, Asian countries; HR =
colorectal,
prostate,
lung,
hepatic, and ovarian cancer, etc.
0.67,
95% CI: 0.52–0.85,
Western
countries).
countries).
This is the first review article and meta-analysis on this topic. Publication of this
article may have potential to impact treatment options in such patients.
All the authors declared no conflict of interest. A title page in enclosed to identify all
authors.
Thank you for your time, attention, and consideration.
© AlphaMed Press 2014
10
11
Manuscript Preparation（稿件的准备）
Compliance with journal guidelines makes it easier to evaluate
your submission. 依从期刊要求使你的文章更容易评估
• Follow the journal’s instructions regarding:
在以下方面遵循期刊投稿须知上的要求
Formats and lengths 形式与长度
o Graphic sizes 图表大小
o Types of supplemental data 补充数据的类型
o
•
•
•
Use proper grammar, punctuation, and language
使用合适的语法、标点及语言
Check that data and results within all text and accompanying
materials are internally consistent
检查文章中的数据与结果，确定资料间的一致性
Be as transparent as possible when disclosing the research
question, how the study was conducted, and what findings
are included.
在公布研究问题、研究实施方法及结果时做到尽可能透明化
© AlphaMed Press 2014
12
Manuscript Preparation （稿件的准备）
Major Challenges for Authors 对于作者要求
●
●
●
Keeping up-to-date with original sources and reviewing the
literature
不断更新原始资料和文献回顾
Providing complete disclosure statements
提供完整的披露申明
Addressing the utility and importance of drugs not currently
available in authors’ home countries
说明在作者本国不通用药品的使用情况以及其重要性
© AlphaMed Press 2014
13
Manuscript Preparation（稿件的准备）
Mistakes to Avoid 可避免的一些错误
●
Missing and/or illegible pages 缺页或者页面不清楚
●
Visible comments by internal reviewers 内部审阅者的评论
●
Poor grammar and typographical errors 语法、排字上的错误
●
●
●
Failing to ensure that all authors have read and approved the
submission 其他作者未阅读稿件及同意投稿
Submitting to multiple journals at once and noting the wrong journal in
the cover letter (Duplicate submission)
一次向多个期刊投稿而在投稿信中混淆期刊名称（重复投稿）
Duplicate publication 重复发表
© AlphaMed Press 2014
14
Manuscript Preparation（稿件的准备）
Mistakes to Avoid 可避免的错误
●
●
●
●
●
●
Rambling text and formatting errors
杂乱无章的全文及格式错误
Over-interpretation, uncritical discussion
过度解释、不重要的讨论
Excessive length, references, and figures
篇幅过长，参考文献与图表过多
Figure legends and text that do not match
图表解释部分与文章内容不一致
Lack of senior authorship involvement in writing introduction and
discussion
在写前言和讨论时，缺少年资较高的作者参与
Lack of proper acknowledgment of authorship and other contributors
(e.g., medical “ghost” writers)
缺少感谢作者及其他贡献者的参与（例如：医学“影子”作者）
© AlphaMed Press 2014
15
Submission Types（投稿类型）
●
Original Articles 原创研究
●
Review Articles 综述文章
●
Brief Reports 简短报告
●
Letters to the Editor 给编辑的信
●
Case Discussions 病例研讨
●
Clinical Trial Results 临床试验结果
© AlphaMed Press 2014
CSCO Case Discussions
●
●
Case Discussions are useful for reporting: 病例研讨可汇报以下内容
–
Unreported or unusual side effects or adverse interactions involving
medications 未报道过的、罕见的药物副作用或者药物间的不良相互作用
–
Unexpected or unusual presentations of a disease
意外的或者罕见的疾病表现
–
Presentations, diagnoses and/or management of rare diseases
罕见疾病的表现、诊断、处理
–
An unexpected association between diseases or symptoms
疾病间或者症状间意外的相关性
–
An unexpected event in the course of observing or treating a patient,
including adverse events
在观察或者治疗病人过程中一些意外的事件，包括不良反应事件
Case Discussions should have obvious educational merit
病例研讨应具有显著的教育意义
© AlphaMed Press 2014
16
CSCO Case Discussions
●
●
●
●
●
Partnered with Chinese Society of Clinical Oncology
Foundation and Chinese Society of Clinical Oncology
(CSCO)
与北京市希思科临床肿瘤学研究基金会和中国抗癌协会临床肿瘤学
专业委员会合作
Moderated by Professor LU Shun from Shanghai Chest
Hospital, expert panel of oncologists discusses patient cases in a
live Internet forum 由上海市胸科医院的陆舜教授指导，肿瘤专
家组以在线论坛的形式讨论疑难病例
Enables other oncologists to participate in a virtual dialogue
促使其他肿瘤学家参与实质性的多方对话
Available through the support of CSCO & STO
在CSCO与STO的支持下实现
Milestone in cancer education by The Oncologist in China
《肿瘤学家》期刊在中国开展肿瘤教育的里程碑
© AlphaMed Press 2014
17
18
Clinical Trial Results （临床试验结果）
An article type designed to encourage the reporting of
all clinical trial results 一种鼓励报告临床结果的文章形式
●
Rapidly publish results that provide
insight into pharmacology, drug
interactions, and reason(s) for drug
failure
●
Combination format 文章格式
–
作者总结：摘要+简要讨论+1至2个
图表
对提供具有深度的药理学、药物相互
作用及用药失败的结果给予快速发表
●
Publishes positive and negative
trials; encourages transparency of
clinical trial results
–
汇报阳性与阴性结果；鼓励临床试验
的透明度
●
Author Summary: abstract + brief
discussion + 1 or 2 salient graphics
Fully indexed by PubMed, ensuring
thorough access to results worldwide
被PubMed收录，可供全球读者阅览
© AlphaMed Press 2014
Full data set + extended discussion
available online
完整的数据集+扩展的在线讨论
19
© AlphaMed Press 2014
20
Cover Letters （投稿信）
This is the first summary of your article and first chance
to convey its significance and relevance.
这是对你的文章的首次总结，也是展现文章重要性和相关性的首次机会
•
•
•
•
Explain why the selected journal is the right place to publish
your article
解释你的论文为何适合发表在该期刊
Describe how your article will advance the field
叙述你的论文如何推动相关研究领域的发展
Continue journal-author dialogue
继续期刊-作者间的对话
Disclose any prior submissions
公开先前投稿情况
© AlphaMed Press 2014
21
Cover Letters (投稿信）
Best Practices 最优方法
•
•
•
•
•
•
Clearly articulate the purpose of the article
清晰地阐明文章目的
Be open-minded and respectful 开明、尊重
Remind editors of previous communications (e.g., presubmission inquiries)
提醒编辑先前的交流（例如：投稿前询问信）
Show interest in issues of importance to the journal:
关注对期刊重要的问题
o Regulatory requirements 药物监管要求
o Conflict of interest disclosures 利益冲突的公开
o Authorship and contributorship criteria 作者与贡献者的标准
Mention prior submissions 提及先前的投稿情况
o Helps editors evaluate improvements made to a manuscript
帮助编辑评估稿件的改正情况
Utilize the cover letter template (please see handout)
使用投稿信的模版
© AlphaMed Press 2014
Cover Letter: Example #1
On behalf of my colleagues, I would like to submit to The Oncologist this manuscript
of original research entitled “EGFR and KRAS Mutation Heterogeneity and the Mixed
Response
to EGFR Tyrosine
Kinase
Inhibitors
in （总结结果）
Non-Small
Cell Lung Cancer”. All
HIGHLIGHT
WHAT
IS
UNIQUE
（突出研究特点）
SUMMARIZE
THE
FINDINGS
Explain
the Impact
（解释其影响）
authors
of
this
research
paper
have
directly
participated
in the planning,
execution,
or
Our
study
is,
thus
far,
the
largest
reported
study
on
In addition,
total,
paired
from
a database
of 3071
tumors
In
our
provide
aCommittee
potential
forEditors
the
analysis
of the 239
study
andresults
metsamples
International
ofexplanation
Medical
Journal
heterogeneity.
(ICMJE)
criteria.
were
identifiedandfor
assessment
of give
EGFR/KRAS
mixed
response
TKI the
resistance,
which may
foundation
heterogeneity
by the
direct
201
were left
for
future
and sequencing.
therapeutic
approaches.
Our
study
is, diagnostic
thus far,
largest
reported study
oncases
heterogeneity.
after
the elimination of patients receiving TKI which including 54
In total, 239 paired samples from a database of 3071 tumors were identified
synchronous
andheterogeneity
147 metachronous
tumor.
for the
assessment of tumor
EGFR/KRAS
by direct sequencing.
201
cases
were left after mutations
the elimination
of patients receiving
TKI which including
EGFR/KRAS
heterogeneity
is indeterminate
in T,54
synchronous
tumorgroups
and 147
metachronous
EGFR/KRAS
mutations
N, and M1b
while
significant tumor.
in patients
with multiple
heterogeneity is indeterminate in T, N, and M1b groups while significant in
pulmonary
nodule
and nodule
metachronous
tumor.tumor.
The The
presence
patients
with multiple
pulmonary
and metachronous
presence
of multiple
pulmonarypulmonary
tumors shouldtumors
not preclude
the second
resection.
of multiple
should
not surgical
preclude
the
second surgical resection.
In addition, our results provide a potential explanation for the mixed response
and TKI resistance, which may give foundation for future diagnostic and
therapeutic approaches.
© AlphaMed Press 2014
22
Cover Letter: Example #2
HIGHLIGHT WHAT IS UNIQUE （突出研究特点）
SUMMARIZE
THE
Sorafenib
is recommended
as FINDINGS（总结结果）
standard （解释其影响）
care for patients with hepatocellular carcinoma
EXPLAIN
THE
IMPACT
(HCC)
and
portal vein tumor
thrombus
(PVTT).
However, there
is a need to develop
This
manuscript
reports
the first
prospective
study
These
findings
would
be
help
for
oncologists
treating
A
consecutive
of
126
patients
were
enrolled
and
to level,
alternative treatments in settings where sorafenib is not feasible atassigned
a population
comparing
surgical
resection
with
best
supportiveThe
careresults
(BSC).
because
developing
countries
accounted
85%
of all
HCC occur globally.
The long-term
patients
who
have
no
access
to
sorafenib.
receive
surgical
resection
or for
BSC
as
treatments.
efficacy and safety of surgical resection in these patients is lacking in evidence.
showed that at an aggressive strategy based on surgical
This
manuscriptprovided
reports the first
prospective
study comparing
surgicalin
resection
with best
resection
a 74.2%
relative
reduction
the risk
of
supportive care (BSC).
death compared with BSC, and provided a 13.7% 5-year
A consecutive of 126 patients were enrolled and assigned to receive surgical resection or
survival
rate. The
While
3-year strategy
survivors
BSC
BSC
as treatments.
resultsthere
showed was
that atno
an aggressive
based in
on surgical
resection
arm. provided a 74.2% relative reduction in the risk of death compared with BSC, and
provided a 13.7% 5-year survival rate.While there was no 3-year survivors in BSC arm.
These findings would be help for oncologists treating patients who have no access to
sorafenib.
© AlphaMed Press 2014
23
Cover Letter: Example #3
HIGHLIGHT WHAT IS UNIQUE （突出研究特点）
SUMMARIZE
THE
FINDINGS
（总结结果）
EXPLAIN
IMPACT
（解释其影响）
This
manuscript THE
has been
read
and approved
for submission by all authors who
In
this work
we
highlight
a case
of
coexistent
have
contributed
to the
manuscript.
A
triad
of diabetes
insipitus,
hyperprolactinemia
andall
After
the
case
report,
we
further
analyzed
Langherhans cell histiocytosis (LCH) and Erdheim-
In pituitary
this
work westalk
highlight
a case
of coexistent
Langherhans
cellhospital
thickening
on diagnosed
MRI is
considered
to be
patients
with
LCH
or ECD
in our
Chester
disease
(ECD)
which
is
a of
very
rare
condition
histiocytosis
(LCH)
and
Erdheim-Chester
disease
(ECD)
which
isHanda very
helpful
to
diagnose
HSC
at onset
the
disease.
We
in
the
past
8
years.
Eosinophilic
granuloma,
rare
condition
in
clinical practice.
This is the first systemic study in the
in
clinical
practice.
…
believe
the paper willdisease
be of interest
both ECD are
schuller-Christian
(HSC)toand
field
from China.
oncologists
compared. and endocrinologists.
After
theis
case
further analyzed
withfrom
LCH or ECD
This
thereport,
firstwe
systemic
study all
inpatients
the field
diagnosed in our hospital in the past 8 years. Eosinophilic granuloma,
China.
Hand-schuller-Christian
disease (HSC) and ECD are compared.
A triad of diabetes insipitus, hyperprolactinemia and pituitary stalk
thickening on MRI is considered to be helpful to diagnose HSC at onset of
the disease. We believe the paper will be of interest to both oncologists and
endocrinologists.
© AlphaMed Press 2014
24
Learning Objectives/Gap Analysis （学习目标/缺口分析）
●
●
●
25
Gap Analysis 缺口分析
–
Describe the best practice concerning the topic of the manuscript, the current practice, and
the “gaps” between them (e.g., what needs to be learned on the subject). Explain how the
article will bridge the gap and describe the impact that the article will have on readers’
competence or performance and/or how the articles might ultimately impact patients’ health.
–
描述与稿件题目相关的最佳临床实践，现行的临床实践，以及他们之间的“缺口” （例如：
关于这个问题我们还需了解什么）。解释论文怎样补充此研究缺口，以及描述论文对读者的
影响，或者描述论文最终会怎样影响患者的健康。
Learning Objectives 学习目标
–
The gaps described by in the Gap Analysis should lead to learning objectives explaining
what new information a reader will gain from reading the article.
–
“缺口分析”应该引出“学习目标”，解释读者通过阅读论文可以获得什么新信息。
Implications for Practice / Impact Statement
对临床实践的意义/影响力申明
–
A brief summary statement that describes the overarching significance of the article. It
should clearly define the potential impact and importance of the manuscript, especially in
terms of its clinical applications.
–
以一个简短的总结描述论文的重要性。总结应该清楚地定义论文带来的影响及其重要性，尤
其是在临床应用方面的重要性。
© AlphaMed Press 2014
26
Editorial Review （编辑审查）
●
●
Upon submission, Editors assess:
投稿后，编辑将会评估：
–
Suitability for the journal
是否适合发表在该期刊
–
Strength of the methods
研究方法的验证强度
–
Value to the field
对于该领域的价值
Based on the assessment, the manuscript will either be reviewed
externally or rejected without external review
根据评估结果，稿件会受外部同行审稿，或者被拒稿
© AlphaMed Press 2014
Review, Revise and Resubmit
（审稿、修稿、再次投稿）
This is your opportunity to address all reviewer and
editorial comments
这是你回复审稿者及编辑提出的意见的机会
Specific guidance about a journal’s review system are often
found in the Instructions to Authors and can help set
appropriate expectations regarding the review process and
projected timeline.
在投稿须知中可找到有关期刊审稿程序的具体指南，借此可对整
个审稿过程及时间有所了解。
© AlphaMed Press 2014
27
Review, Revise and Resubmit（审稿、修稿、再次投稿）
Best Practices 最优方法
• Remember that reviewers’ comments are meant to be helpful
记住审稿者的反馈建议对你是有帮助的
• Follow journals’ guidelines for revising manuscripts
遵从期刊的投稿者指南中提到的修改稿件的要求
o
Respond systematically to each point raised by the reviewers in a cover letter
系统地一一回应审稿者的反馈建议
o
File formats (e.g., Word document with tracked changes)
文件的格式（例如：有修改印记的Word稿件）
•
Address all reviewer and editorial comments point by point
一一回应审稿者和编辑的反馈建议
o
If a reviewer’s comment is viewed to be incorrect or unjustified, provide an
explanation and supportive literature references
• Avoid easy fixes - these are often transparent to editors
避免简单的修改，这些对编辑们来说是很明显的
• Address all reviewers’ comments, even if submitting elsewhere
即使向其他期刊投稿，也要回应所有审稿者的评论
• Stay open-minded if your article is not accepted
即使文章没被接受，也要保持开明的态度
© AlphaMed Press 2014
28
29
Revision: Example #1
Reviewer
2:
Editors: 1:
The
authors’
that
patients
with multiple
nodules
should
be
considered
Please
address
potential
error.You
describe
tumors
that
arethe
supposedly
EGFRfor
WT-MUT
Please
note conclusion
that
both sampling
of the
reviewers
and thelung
editor
found
results
section
quite
resection
a bold
statement,
they
should
based
ontodata
the
number
nodulesanalyses
that the
(ie
WT in is
primary,
mutant
in metastasis).
would
seem
me aonhighly
unlikely
scenario,
while
confusing
as
written.
There
should
beItclarify
clearer
explanations
of why
theof
various
should
be
considered
as plausible.
a were
patientdone.
with10
lung is
nodules
versusthat
2 nodules
are most
a very
different case.
reverse
would
beanalyses
more
MoreConsider
likely
thesummarizing
concept
the
is heterogeneous,
and subgroup
onlyprimary
the
important
and
you only
sampled
and analyzed
a WT portion.
in the
Discussion
results
in the
text itself
while making
clearerPlease
tablesaddress
to display
the
full data.section.
Response:
sentence
has been
amended based
theenhanced
reviewer’sin
suggestion.
(page
Response: The
Refer
to WT-MUT,
a paragraph
have on
been
the discussion
19,
line as
371
to line 377):The
ofpresent
multiple
synchronous
or metachronous
section
requested:
There
arepresence
5 patients
WTwhy
in primary
tumor
while
Response:
In the revised
manuscript,
we have
madewith
it clear
the various
analyses
pulmonary
tumors
with
N0,
and
no
extra-thoracic
involvement
should
not
preclude
mutant
in metastases.
be originated
from theonly
heterogeneity
thea
and subgroup
analysesThese
weremight
performed,
summarizing
the most within
important
second
surgical resection.
However,
whether
patients
with multiple
nodules
primary
(page19,
354
line 365).
In data.
addition,
the pastlung
Table
1 has
results incarcinomas
the text, using
clear line
tables
toto
display
the full
should
be
considered
for
resection
based
on
many
factors
besides
humor
been described by text.
heterogeneity (multiple primary lung cancers or distant metastasis), including
nodules number, location, and tumor size.
© AlphaMed Press 2014
Revision: Example #1
More Reviews/More Revisions（多次审稿和多次修稿）
●
Two more rounds of revision 两轮的修稿程序
–
–
●
30
Thoughtful, incisive reviews 深思熟虑、一针见血的审阅
Measured, comprehensive response from authors
来自作者的权衡及全面的回复
In the end — SUCCESS
最终稿件被成功接受
–
Published in 2012, this article is one of the most read and most
cited papers in The Oncologist during the past two years.
该论文在2012年发表，是在过去两年中该期刊被阅读与引用次数最
多的论文
© AlphaMed Press 2014
31
Peer Review: Example #2
●
●
●
●
The control arm was not offered TACE or any other therapy. This is
not best supportive care. There is no surprise that the surgical
treated patients did better.
The safety and efficacy of TACE in HCC is well proven. It is unclear
why the BSC group was not offered this treatment.
It does not seem plausible that 100% of patients had tumors >7cm,
with 48/86 having >1 tumor, but only 16/86 were bilateral. Was there
an inaccuracy in pre-op imaging?
It seems to be ethically unacceptable to conduct the controlled study
between well-established and potentially curative treatment
(resection) and BSC, setting two-times longer median survival
between the two arms. Did the patients in the BSC arm have any
non-medical reasons to refrain from surgical treatment? And what
kind of the treatment was adopted for 137 patients who met the
inclusion criteria but refused to participate in this study?
© AlphaMed Press 2014
32
Peer Review: Example #2
FLAWS IN THE STUDY DESIGN
•
•
The control arm was not offered TACE or any other therapy. This is not best
supportive care. There is no surprise that the surgical treated patients did better.
The safety and efficacy of TACE in HCC is well proven. It is unclear why the BSC
group was not offered this treatment.
QUESTIONS ABOUT THE DATA
•
对于数据提出的问题
It does not seem plausible that 100% of patients had tumors >7cm, with 48/86 having
>1 tumor, but only 16/86 were bilateral. Was there an inaccuracy in pre-op imaging?
ETHICAL CONCERNS
•
研究设计上的缺点
伦理问题
It seems to be ethically unacceptable to conduct the controlled study between wellestablished and potentially curative treatment (resection) and BSC, setting two-times
longer median survival between the two arms. Did the patients in the BSC arm have
any non-medical reasons to refrain from surgical treatment? And what kind of the
treatment was adopted for 137 patients who met the inclusion criteria but refused to
participate in this study?
REJECTED（拒稿）
© AlphaMed Press 2014
33
Revision: Example #3
Up
now,
most expand
of the the
cases
about
LCHappearances
ECD
wereofreported
from
Cantothe
authors
detail
onradiographic
the
etiology
oforthe
pituitary
stalk
osteolysis
thickening?
vs.Western
How
countries.
Sincewhich
this isisfrom
the
first
systemic
study
inthe
thekey
fieldpoints
from China,
the
osteosclerosis,
can
it be differentiated
essential
a intracranial
to understand
germinoma?
of the manuscript?
authors should provide more background information of those diseases in
Response: In
lightwith
of the
of pituitary
stalk of
is
Wethe
agree
thecomment,
comment,thickening
radiographic
appearances
China.
highlighted
inosteosclerosis
the discussion.
Differential
diagnosis
between
LCH and
osteolysis vs.
have
been introduced
in the
discussion
germinomaAccording
is elaborated
in the
first paragraph
page 11. in the field have
Response:
to the
comment,
Chineseon
literatures
been reviewed in the discussion
© AlphaMed Press 2014
34
Revision: Example #3
●
●
●
Accepted!
A rare case report to be accepted as a CME (continuing
medical education) course.
CME Learning Objectives
–
Distinguish Erdheim-Chester disease from Langerhans cell histiocytosis.
–
Cite the keys to diagnosis of Hand-Schüller-Christian disease in a patient
with only central diabetes insipidus.
–
List the signs linking a Hand-Schüller-Christian disease patient to
coexisting ECD.
© AlphaMed Press 2014
Example #3: Learning Objectives,
Gap Analysis & Implications for Practice
Learning
Objectives:
Gap
Analysis:
1. knowPractice
howfor
to differentiate
from
LCH.
Implications
Practice: ECD
Current
Best
Practice
The Resulting Gap
2.
Keys
to
diagnose
HSC
in
a
patient
with
only
central
diabetes
insipidus.
CDI is usually the final diagnosis. For a patient with CDI presentation, Make
a diagnosis of HSC at the
3.
Signs
to
link
a
HSC
patient
to
coexisting
ECD.
Central
diabetes
insipitus
(CDI) pituitary
is usually
first
or prolactin
one of the first
symptoms
ofdisease.
HandThe physicians
seldom
think the
MRIthe
and
blood
early
stage of the
Schüller-Christian
disease (HSC).
is difficult
CDI may be part of HSC.
testItmay
be usedtofordetermine
differential whether CDI is part of HSC at its
onset.
diagnosis. If pituitary stalk
thickening and hyperprolactinemia
We propose a new triad of symptoms
including
central
insipitus, hyperprolactinemia,
are observed
in the
patient,diabetes
HSC
and pituitary stalk thickening on should
MRI. Ifbeaconsidered
patient presents
with the triad, HSC should be
and a bone
considered.
scan is necessary.
Physicians seldom think a HSC
If osteosclerosis appears in a
Facilitate the diagnosis of ECD.
Bone
aresuffer
very from
useful
to reveal
in thethe
absence
of bone pain. Langerhans cell
patientscans
may also
ECD.
patientHSC
with HSC,
coexistence
histiocytosis (LCH) and Erdheim-Chester
disease
(ECD) are
of ECD should
be considered
andfeatured with osteolytic lesions
and osteosclerosis, respectively.new
If osteosclerosis
is observed in a patient with LCH,
biopsy is needed.
coexistence
should
A new
biopsy
for the
diagnosis.
The diagnosisof
of ECD
LCH or
ECD isbe considered.
LCH is featured
as lytic
boneis helpful
Make
a primary
diagnosis of
dependent on postoperative
lesions, elevated plasma ALP level. LCH or ECD prior to surgery.
histopathological examination.
ECD is featured as osteosclerosis
and normal ALP level.
© AlphaMed Press 2014
35
36
Example #3: CME Case
A 36-year-old male is referred to your clinic
with complaints of severe polyuria and
extreme thirst that have lasted for several
months. A water deprivation and
desmopressin test reveal central diabetes
insipidus (CDI). MRI shows pituitary stalk
thickening. A blood test came back showing
slightly increased prolactin. Which of the
following is correct?
a. He may have Hand-Schüller-Christian
disease.
b. A bone scan is indicated.
c. CDI is an isolated disease and needs no
further investigation.
d. CDI is distinguishable from brain tumor
such as germinoma and
craniopharyngioma.
e. A and B
f. C and D
A bone scan shows increased radionuclide
uptake in the right zygoma, temporal bone,
mandible, thoracic vertebra, and ribs.
Osteolysis is observed in his X-ray images.
Which of the following is incorrect?
a. He is likely to be diagnosed with HandSchüller-Christian disease
b. Biopsy may reveal Langerhans cell
histiocytosis.
c. He is likely to be diagnosed with
Erdheim-Chester disease.
d. He may suffer from Erdheim-Chester
disease in the future.
© AlphaMed Press 2014
Acceptance & Rejection （接受及拒稿）
37
Acceptance includes, but is not limited to:
被接受的稿件优点包括，但不局限于：
●
Importance of the research to the field of oncology 肿瘤领域中的重要研究
●
Originality of the work 研究的原创性
●
Quality of the study 研究的质量
●
Priority of the work to the Journal and its readership 对于期刊和读者来说具有
重要性
Papers are rejected if they are:
以下情况，论文会被拒稿:
●
●
●
Not relevant to oncology practice issues 与肿瘤学实践无关
Case reports not of educational benefit/relevance to the practitioner 无教育意
义的病例报告; by invitation from the editors only 仅仅由编辑邀请投稿
Written by a ghost writer, paid by a commercial interest, promotional or not fair
and balanced.由“影子”作者撰写，受商业利益驱使等
●
Raise ethical concerns 引起伦理上的疑问
●
Do not add significantly to the existing literature 对已有的文献没有贡献
© AlphaMed Press 2014
Next Steps After Rejection
(拒稿后采取的步骤）
Following rejection, authors generally have two choices:
拒稿后，作者一般有两种选择
• Appeal the decision 反驳该期刊的拒稿决定
• Submit the manuscript to another journal 向其他期刊投稿
o Refer to the original list of researched journals and reconsider those identified as having a strong fit
参考原先搜查过的期刊目录，重新考虑向合适的期刊投稿
Some journals will respond to follow-up questions.
一些期刊会回应一些后续的问题
•
Engage in open dialogue about the editors’ notes to develop a
more effective new submission strategy
作者应与编辑积极开展对话，开发更加有效的投稿策略
Some journals may share submissions with partner journals if a
submission may be more appropriate for one of the partners.
一些期刊与其伙伴期刊可能会共同分享稿件，并相互推荐。
© AlphaMed Press 2014
38
39
Goals: The Oncologist’s Editorial Board
宗旨：《肿瘤学家》期刊编辑委员会
●
●
To encourage meaningful reviews and state-of-the-art
papers
鼓励具有意义的综述和最新水平的论文
To encourage original work that has relevance and
impact on the practice of oncology
鼓励与肿瘤学实践有关并对其具有影响的原创性研究
●
●
To keep pace with programs at the clinical frontier, and
to encourage a bit of exploration at the same time
跟进临床实践的尖端技术，同时也鼓励创新性探索
To keep our readership informed of the latest
developments in clinical care and clinical research in
each area of specialization
使我们的读者时刻了解每个副领域内最新的研究与临床进展
http://authors.theoncologist.com
© AlphaMed Press 2014
Additional Resources （更多资源）
Toolkit Manuscript （文献工具包）– Chipperfield, et al. (2010). Authors'
Submission Toolkit: A practical guide to getting your research published,
CMRO, 26:8, 1967-1982.
The Oncologist（肿瘤学家期刊网址）: http://authors.theoncologist.com/
• Contains more detailed discussion of topics and additional information
on submission best practice
包括相关议题的详细内容以及与投稿有关的一些额外信息
International Committee of Medical Journal Editors（国际医学期刊编辑委
员会网址）: http://www.icmje.org
• A comprehensive resource for writing articles for biomedical journals,
including important ethical guidelines
为撰写生物医学期刊论文提供全面的网上资源
Medical Publications Insights and Practices (MPIP) website:
有关医学论文发表的见解与方法的网址 www.mpip-initiative.org
• Provides a database of journals accepting “specialized interest” data
and other helpful resources
提供接受特殊研究方向数据的期刊数据库以及其他一些有用的资源
© AlphaMed Press 2014
40